Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study

Journal of Urology

Volumn 180, Issue 4, 2008, Pages 1228-1234

  Roehrborn, Claus G ^a   McVary, Kevin T ^b   Elion Mboussa, Albert ^c   Viktrup, Lars ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

dose response relationship; drug; prostate; prostatic hyperplasia; questionnaires; tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFLUENZA; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYALGIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; CARBOLINES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 50949119951     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.06.079     Document Type: Article

References (26)

1. Wei J.T., Calhoun E., and Jacobsen S.J. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol 173 (2005) 1256
2. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481
3. Sagnier P.P., MacFarlane G., Teillac P., Botto H., Richard F., and Boyle P. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 153 (1995) 669
4. Norman R.W., Nickel J.C., Fish D., and Pickett S.N. 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 74 (1994) 542
5. American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Guideline Update Panel: Guideline on the Management of Benign Prostatic Hyperplasia (BPH). American Urological Association 2006 (2008). URL:http://www.auanet.org/guidelines/bph.cfm Accessed March 2008
6. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
7. McVary K.T., and McKenna K.E. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep 5 (2004) 251
8. Forgue S.T., Patterson B.E., Bedding A.W., Payne C.D., Phillips D.L., Wrishko R.E., et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 61 (2006) 280
9. Uckert S., Kuthe A., Jonas U., and Stief C.G. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166 (2001) 2484
10. Filippi S., Morelli A., Sandner P., Fibbi B., Mancina R., Marini M., et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148 (2007) 1019
11. Gacci M., Del P.G., Macchiarella A., Celso M., Vittori G., Lapini A., et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178 (2007) 2040
12. Azadzoi K.M., Babayan R.K., Kozlowski R., and Siroky M.B. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 170 (2003) 659
13. Berger A.P., Deibl M., Leonhartsberger N., Bektic J., Horninger W., Fritsche G., et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96 (2005) 1073
14. Pinggera G.M., Mitterberger M., Pallwein L., Schuster A., Herwig R., Frauscher F., et al. Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 101 (2008) 319
15. Andersson K.E., Uckert S., Stief C., and Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26 (2007) 928
16. Ehren I., Iversen H., Jansson O., Adolfsson J., and Wiklund N.P. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 44 (1994) 683
17. Yoshimura N., Seki S., and de Groat W.C. Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 86 (2001) 304
18. Persson K., and Andersson K.E. Nitric oxide and relaxation of pig lower urinary tract. Br J Pharmacol 106 (1992) 416
19. McVary K.T., Roehrborn C.G., Kaminetsky J.C., Auerbach S.M., Wachs B., Young J.M., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 (2007) 1401
20. StatXact Procs for SAS Users: Statistical Software for Exact Nonparametric Inference (User Manual), version 6 (2004), Cytel Software Corp, Cambridge, Massachusetts
21. Barry M.J., Williford W.O., Chang Y., Machi M., Jones K.M., Walker-Corkery E., et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol 154 (1995) 1770
22. Dunn C.J., Matheson A., and Faulds D.M. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 19 (2002) 135
23. McVary K.T., Monnig W., Camps Jr. J.L., Young J.M., Tseng L.J., and van den E.G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177 (2007) 1071
24. Stief C.G., Porst H., Neuser D., Beneke M., and Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53 (2008) 1236
25. Porst H., Giuliano F., Glina S., Ralph D., Casabe A.R., Elion-Mboussa A., et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 50 (2006) 351
26. Rajfer J., Aliotta P.J., Steidle C.P., Fitch III W.P., Zhao Y., and Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 19 (2007) 95